Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: A need for guidelines

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1342-1346

  Van Groeningen, C J ^a   Van Der Vijgh, W J F ^a   Baars, J J ^a   Stieltjes, H ^a   Huibregtse, K ^b   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; TUMOR VACCINE; UFT;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; NEUTROPENIA; PRIORITY JOURNAL; SEPTICEMIA; SIGMOID CARCINOMA; SIGMOIDECTOMY; SOMNOLENCE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; COLONIC NEOPLASMS; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LIVER DISEASES; METABOLIC CLEARANCE RATE; MIDDLE AGED; PRACTICE GUIDELINES; SLEEP;

EID: 0034006699     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Creamers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors. Topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
2. Pinot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Maillard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., Levitt, R., and Winschitl, H. E. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J. Clin. Oncol., 15: 2910-2919, 1997.
3. Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong. W. P., Chou, T. C., Sun, M., Pulliam, S., and Gonzalez, C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 709-715, 1996.
4. Cunningham, D., Pyrhonen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., and Herait, P. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352: 1413-1418, 1998.
5. Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., Awad, L., Herait, P., and Jacques, C. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352: 1407-1412, 1998.
6. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., and Sato, K. Intracellular roles of SN-38, a metabolite of camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51: 4187-419, 1991.
7. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
8. Iyer, L., and Ratain, M. J. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol., 42: 531-543, 1998.
9. Chu, X. Y., Kato, Y., Keda, K., Suzuki, H., Niinuma, K., Tyson, C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., and Sugiyama, Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res., 58: 5137-5143, 1998.
10. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., deForni, M., Extra, J. M., Mahjoubi, M., Herait, P., Armand, J. P., and Bugat, R. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann. Oncol., 6: 141-151, 1995.
11. Vermorken, J. B., Claessen, A. M. E., Van Tinteren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Meijer, C. J. L. M., Bloemena, E., Ransom, J. H., Hanna, M. G., and Pinedo, H. M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353: 345-350, 1999.
12. Rivory, L. P., and Robert, J. Reversed-phase high-performance liquid chromatographic method for the quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. B Biomed. Appl., 661: 133-141, 1994.
13. Rivory, L. P., and Robert, J. Identification and kinetics of a (3-glucuronide of SN-38 in human plasma after administration of the camptothecin derivative irinotecan (CPT-11). Cancer Chemother. Pharmacol., 36: 176-179, 1995.
14. Gibaldi, M., and Perrier, D. Pharmacokinetics, 2nd ed., Chap. 11, pp. 409-418. New York: Marcel Dekkers, Inc., 1982.
15. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., and Rodriguez, G. I. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol., 11: 2194-2204, 1993.
16. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
17. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., Misset, J. L., and Cvitkovic, E. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol., 8: 1049-1051, 1997.
18. Raymond, E., Vernillet, Boige, V., Hua, A., Ducreux, M., Faivre, S., Jacques, C., Gatineau, M., Mignard, D., Vergniol, J. C., Rixe, O., and Armand, J. P. Phase I and pharmacokinetic study of irinotecan (CPT-11) in cancer patients with hepatic dysfunction. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 165a, 1999.